As of September 29, 2026, Edgewise Therapeutics's top three insider holders are Advisors Llc Orbimed (Director, 13.98Mn shares), Peter A. Thompson (Director, 13.98Mn shares), Holdings A/S Novo (TenPercentOwner, 6.07Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Holdings A/S Novo | TenPercentOwner | 6,071,703 | 0 | 6,071,703 | 83.9% | 16 Sep, 2022 |
| 2 | Peter A. Thompson | Director, TenPercentOwner | 0 | 443,792 | 443,792 | 6.1% | 04 Apr, 2025 |
| 3 | Advisors Llc Orbimed | Director, TenPercentOwner | 0 | 443,792 | 443,792 | 6.1% | 04 Apr, 2025 |
| 4 | R Michael Carruthers | Chief Financial Officer | 86,162 | 0 | 86,162 | 1.2% | 14 Aug, 2025 |
| 5 | Kevin Koch | President And Ceo | 52,488 | 0 | 52,488 | 0.7% | 13 Aug, 2026 |
| 6 | Behrad Derakhshan | Chief Business Officer | 31,826 | 0 | 31,826 | 0.4% | 13 Aug, 2026 |
| 7 | Alan J Russell | Chief Scientific Officer | 31,466 | 0 | 31,466 | 0.4% | 13 Aug, 2026 |
| 8 | Jonathan C Fox | Director | 24,833 | 0 | 24,833 | 0.3% | 01 Jul, 2026 |
| 9 | Badreddin Edris | Director | 19,820 | 0 | 19,820 | 0.3% | 21 Jan, 2026 |
| 10 | John R Moore | General Counsel | 17,697 | 0 | 17,697 | 0.2% | 14 Aug, 2026 |
| 11 | Joanne M. Donovan | Cmo | 8,625 | 0 | 8,625 | 0.1% | 13 Aug, 2026 |
| 12 | Marc Semigran | Chief Development Officer | 6,716 | 0 | 6,716 | 0.1% | 27 Dec, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 12 Aug, 2026 | John R Moore | General Counsel | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 12 Aug, 2026 | Alan J Russell | Chief Scientific Officer | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 12 Aug, 2026 | Michael Nofi | Chief Financial Officer | Acquired A | 48,750 | $0.00 | $0 | 48,750 | Direct |
| 12 Aug, 2026 | Behrad Derakhshan | Chief Business Officer | Acquired A | 100,000 | $0.00 | $0 | 100,000 | Direct |
| 12 Aug, 2026 | Joanne M. Donovan | Cmo | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Acquired M | 5,781 | $0.00 | $0 | 15,995 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Acquired M | 6,718 | $0.00 | $0 | 22,713 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed S | 2,439 | $43.81 | $106.85K | 20,274 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed S | 59 | $44.41 | $2.62K | 20,215 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed S | 99 | $44.50 | $4.41K | 20,116 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed S | 2,419 | $43.80 | $105.95K | 17,697 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed M | 5,781 | $0.00 | $0 | 11,563 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Disposed M | 6,718 | $0.00 | $0 | 20,157 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Acquired A | 32,500 | $0.00 | $0 | 32,500 | Direct |
| 12 Aug, 2026 | John R Moore | General Counsel | Acquired A | 65,000 | $0.00 | $0 | 65,000 | Direct |
| 12 Aug, 2026 | Kevin Koch | President And Ceo | Acquired M | 17,969 | $0.00 | $0 | 48,584 | Direct |
| 12 Aug, 2026 | Joanne M. Donovan | Cmo | Acquired M | 5,781 | $0.00 | $0 | 11,035 | Direct |
| 12 Aug, 2026 | Michael Nofi | Chief Financial Officer | Acquired A | 24,375 | $0.00 | $0 | 24,375 | Direct |
| 12 Aug, 2026 | Behrad Derakhshan | Chief Business Officer | Acquired M | 5,781 | $0.00 | $0 | 29,426 | Direct |
| 12 Aug, 2026 | Alan J Russell | Chief Scientific Officer | Acquired M | 5,781 | $0.00 | $0 | 30,336 | Direct |